Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277]

Gynecol Oncol. 2020 Jan;156(1):262. doi: 10.1016/j.ygyno.2019.10.020. Epub 2019 Nov 16.

Authors

V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, P Barretina-Ginesta, M Romeo, G Villacampa, B Pardo, H Ahmed, S Recalde, J M Piulats, M C Gomez-Plaza, A Gil-Moreno, E Sala, S Martínez-Roman, J Ponce, C Melendez, E Carballas, R Dienstmann, A Oaknin

PMID: 31744639
DOI: 10.1016/j.ygyno.2019.10.020

No abstract available

Publication types

Published Erratum